Floatz Rating
CC43/100
Confidence
Indicative
Sponsor
Verinder Sharma
Modality
Small molecule
Development Phase
Phase 1
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
28Moderate confidence
Detailed axis rationale is planned and will be published soon.
No trial-level evidence is linked to this axis yet.
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95Moderate confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Postpartum Depression
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Quetiapine (this asset) | Verinder Sharma | P1 | CC · 43 |
| Allopregnan-3.Alpha.-Ol-20-One | Supernus Pharmaceuticals, Inc. | P3 | BBB |
| Sertraline | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | P4 | BB |
| Zuranolone | Biogen | P3 | BB |
| Gabapentin | Stanford University | P4 | BB |
| Lpcn 1154A | Lipocine Inc. | P3 | BB |
| Escitalopram | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | P3 | BB |
| Celecoxib | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | P3 | B |
| Nora520 | DuKang Pharmaceuticals, Inc. | P2 | B |
+4 more in the Postpartum Depression cohort
Other indications for Quetiapine
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Schizoaffective Disorder | — | P4 | BBB · 76 |
| Bipolar Disorder | — | P4 | BBB · 74 |
| Substance Abuse | — | P4 | BBB · 74 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Quetiapine in Postpartum Depression. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 13, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/quetiapine-postpartum-depression
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →